EUVIMEDEUVIMED entdecken
Crossref

Clinicopathological and Molecular Profile of Sellar Neurocytoma

Yulou Liu, Jing Guo, Jianhua Cheng, Qiuyue Fang, Dawei Wang, Weiyan Xie, Chuzhong Li iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Yulou Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China. Hauptthemen laut MEDLINE: Neurocytoma, Pituitary Neoplasms, Sella Turcica. Die Arbeit nennt 16 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the clinical features, imaging characteristics, and molecular profile of sellar neurocytoma (SN).

Methods

Clinical, imaging, and pathological features of 11 cases of SN were retrospectively analyzed. Electron microscopy was performed in 5 cases. Molecular features were detected in tumor tissue by RNA sequencing, quantitative polymerase chain reaction, and immunohistochemistry.

Results

The clinical features of SN patients showed a high incidence of hyponatremia (73%, 8/11), and the tumors tended to invade the lateral side of the saddle area from preoperative imaging analysis. The tumors had positive NeuN, synaptophysin, neurofilament, somatostatin receptor 2 (SSTR2) immunohistochemistry staining. Tumor transcriptomic analysis suggested a new LMCD1-AS1:GRM7-AS1 fusion gene event and increased expression of 10 hypothalamus-secreted hormones in SN. Fifteen differentially expressed genes were verified for quantitative polymerase chain reaction verification. SSTR2 has been verified by immunohistochemistry.

Conclusion

Hyponatremia is the dominant clinical features of SN. Preoperative imaging suggests that growth toward the dorsal region is the imaging feature of SN. SSTR2 expression and LMCD1-AS1:GRM7-AS1 fusion gene event expected to become a new molecular marker for SN. Somatostatin receptor ligand therapy may be a potential therapy for SN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurocytomaPituitary NeoplasmsSella TurcicaHumansFemaleAdultMaleRetrospective StudiesMiddle AgedReceptors, SomatostatinYoung AdultAdolescentBiomarkers, TumorHyponatremia

Stichwörter der Autor:innen

SSTR2fusion genehyponatremiamolecular profileradiologic characteristicsellar neurocytoma

Substanzen

Receptors, SomatostatinBiomarkers, TumorSSTR2 protein, human

Autor:innen und Institutionen

  • Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.

ORCID-Profile: Chuzhong Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, Y., Guo, J., Cheng, J., Fang, Q., Wang, D., Xie, W., & Li, C. (2025). Clinicopathological and Molecular Profile of Sellar Neurocytoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae260

Vancouver

Liu Y, Guo J, Cheng J, Fang Q, Wang D, Xie W, et al. Clinicopathological and Molecular Profile of Sellar Neurocytoma. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae260

BibTeX
@article{Liu2025,
  author = {Liu, Yulou and Guo, Jing and Cheng, Jianhua and Fang, Qiuyue and Wang, Dawei and Xie, Weiyan and Li, Chuzhong},
  title = {Clinicopathological and Molecular Profile of Sellar Neurocytoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae260}
}
Kostenlos starten →